Hoitt Jason
Chief Patient Officer at STOK; Chief Commercial Officer at Provention Bio, Inc.; Chief Commercial Officer at Dova Pharmaceuticals Inc.
- Sold, on record
- $401k
- Dollars the filings state
- Form 4 sales
- 6
- Latest Mar 18, 2026
- Form 144 notices
- 0
- Proposed sales
- Companies
- 3
- Filed as an executive or holder
Companies
- STOKStoke Therapeutics, Inc.Chief Patient Officer
- Provention Bio, Inc.Chief Commercial Officer
- Dova Pharmaceuticals Inc.Chief Commercial Officer
Sales by reason
Form 4 sales per month, last 12 months.
Sales by company
- Dova Pharmaceuticals Inc.14,741 shares
- Provention Bio, Inc.4,500 shares
- STOK3,712 shares
Shares sold, every Form 4 sale on record.
Timeline
- 1 Form 4 sale Dova Pharmaceuticals Inc.Plan not statedApr 8, 2019 2019
Sold 2,387 shares at $8.77 ($21k)
Hoitt Jason, Chief Commercial Officer
Sold 9.7% of holdings ($217k position)22,324 shares leftFirst sale on recordFiling
- 2 Form 4 sale Dova Pharmaceuticals Inc.Plan not statedJun 28, 2019 +81 days
Sold 2,387 shares at $13.81 ($33k)
Hoitt Jason, Chief Commercial Officer
Sold 10.7% of holdings ($308k position)19,937 shares leftFiling
- 3 Form 4 sale Dova Pharmaceuticals Inc.UnusualJul 15, 2019 +17 days
Sold 7,580 shares at $15.26 ($116k)
Hoitt Jason, Chief Commercial Officer
Sold 38% of holdings ($304k position)12,357 shares leftFiling
- 4 Form 4 sale Dova Pharmaceuticals Inc.Plan not statedSep 30, 2019 +77 days
Sold 2,387 shares at $28.00 ($67k)
Hoitt Jason, Chief Commercial Officer
Sold 19.3% of holdings ($346k position)9,970 shares left1x usual sizeFiling
- 5 Form 4 sale Provention Bio, Inc.UnusualFeb 10, 2023 +1229 days
Sold 4,500 shares at $10.00 ($45k)
Hoitt Jason, Chief Commercial Officer
Sold 100% of holdings ($45k position)0 shares leftFirst sale on recordFiling
- 6 Form 4 sale STOKUnusualMar 18, 2026 +1132 days
Sold 3,712 shares at $32.14 ($119k)
Hoitt Jason, Chief Patient Officer
No 10b5-1 planSold 26.5% of holdings ($450k position)10,276 shares leftFirst sale on recordFiling
Every transaction
Loading transactions…
Sales and notices (6)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Mar 18, 2026 | Mar 19, 2026 | STOK | Chief Patient Officer | Form 4 sale | 3,712 | $119k | 26.5% | Unusual | SEC |
| Feb 10, 2023 | Feb 14, 2023 | Provention Bio, Inc. | Chief Commercial Officer | Form 4 sale | 4,500 | $45k | 100.0% | Unusual | SEC |
| Sep 30, 2019 | Oct 2, 2019 | Dova Pharmaceuticals Inc. | Chief Commercial Officer | Form 4 sale | 2,387 | $67k | 19.3% | Plan not stated | SEC |
| Jul 15, 2019 | Jul 16, 2019 | Dova Pharmaceuticals Inc. | Chief Commercial Officer | Form 4 sale | 7,580 | $116k | 38.0% | Unusual | SEC |
| Jun 28, 2019 | Jul 2, 2019 | Dova Pharmaceuticals Inc. | Chief Commercial Officer | Form 4 sale | 2,387 | $33k | 10.7% | Plan not stated | SEC |
| Apr 8, 2019 | Apr 10, 2019 | Dova Pharmaceuticals Inc. | Chief Commercial Officer | Form 4 sale | 2,387 | $21k | 9.7% | Plan not stated | SEC |